Finklestein J Z, Tittle K, Rubenstein J, Meshnik R, Weiner J
Med Pediatr Oncol. 1976;2(3):279-89. doi: 10.1002/mpo.2950020309.
The C1300 murine neuroblastoma system has been studied to determine its relevance as a chemotherapy model to the human disease. Studies using combination therapy revealed that BCNU/cyclophosphamide combination therapy increased the median lifespan 300% in A/J mice bearing the C1300 tumor. Cyclophosphamide/imidazole carboxamide and adriamycin/imidazole carboxamide combinations were less active, increasing median lifespans 189% and 144%, respectively. Vincristine/bleomycin were inactive even when the schedule was adjusted to coincide with the time of maximum mitoses following vincristine injections. These results suggest the BCNU/cyclophosphamide combination chemotherapy may be effective in human disease.
已对C1300小鼠神经母细胞瘤系统进行研究,以确定其作为人类疾病化疗模型的相关性。使用联合疗法的研究表明,在携带C1300肿瘤的A/J小鼠中,卡莫司汀/环磷酰胺联合疗法使中位生存期延长了300%。环磷酰胺/咪唑甲酰胺和阿霉素/咪唑甲酰胺联合疗法的活性较低,分别使中位生存期延长了189%和144%。即使调整给药方案使其与注射长春新碱后最大有丝分裂时间一致,长春新碱/博来霉素联合疗法仍无活性。这些结果表明,卡莫司汀/环磷酰胺联合化疗可能对人类疾病有效。